Fresenius Medical Care Share Reaction to CMS Reimbursement Proposal

On 25 June 2026, shares of Fresenius Medical Care (ticker ETR:FMEG) declined roughly 5% after the U.S. Centers for Medicare & Medicaid Services (CMS) released a draft proposal to adjust dialysis reimbursement. The regulator suggested a 1.1% increase to the base rate for the end‑stage renal disease (ESRD) bundle payment, which is about half of the roughly 2% rise that investors had been expecting and well below the increases observed in previous years.

CMS further announced that, beginning in 2027, phosphate binders will be incorporated into the ESRD bundle. This change eliminates the separate payment mechanism that has historically driven strong uptake of Fresenius’s phosphate‑binder drug Velphoro. UBS analysts, led by Graham Doyle, indicated that the bundling is likely to reduce Velphoro utilisation, drawing a parallel to the earlier transition of calcimimetics when they moved from add‑on payments to the bundle. The analysts expect the profit pool associated with Velphoro to fall significantly for Fresenius in 2027.

The analysts noted that market hopes of a one‑year delay in the phosphate‑binder transition were unlikely to materialise, describing the proposal as “likely to disappoint.” While CMS retains the ability to revise the final rate upward—last year’s final rate was 30 basis points above the draft—the analysts warned that even a modest upward adjustment would probably still result in a margin drag for Medicare‑covered patients.

Key Figures

  • Share price impact: ~5% decline.
  • Proposed ESRD bundle base‑rate increase: 1.1% (≈50% of market expectation).
  • Expected increase that investors had anticipated: ~2%.
  • Phosphate‑binder bundling effective year: 2027.
  • Last year’s final rate adjustment: +30 basis points over draft.

Analyst Commentary

UBS described the CMS proposal as “worse than usual,” emphasizing that the lower-than‑expected rate increase and the inclusion of phosphate binders could materially compress Fresenius’s profit margins, particularly through reduced Velphoro utilisation.